公开(公告)号：US20200377594A1

公开(公告)日：2020-12-03

申请号：US16635303

申请日：2018-08-13

Applicant: MORPHOSYS AG

Inventor： Thomas TILLER ,  Steffen RUNZ ,  Julia NEUGEBAUER ,  Andreas BÜLTMANN

IPC: C07K16/28 ,  C07K16/32

Abstract: The present disclosure provides humanized antibodies that specifically bind to CD3 with an optimized affinity and induce T cell-mediated killing of tumour related target antigen high expressing cells with high potency but have limited killing activity on target antigen low expressing cells. The present disclosure also provides bispecific antibodies comprising a first antigen-binding domain that specifically binds to human CD3 with optimized affinity and a second antigen-binding molecule that specifically binds a tumor-related antigen. The disclosure further relates to methods of generating such humanized antibodies and bispecific antibodies for biological, diagnostic, pharmaceutical and other uses.

公开(公告)号：US20190062422A1

公开(公告)日：2019-02-28

申请号：US16184390

申请日：2018-11-08

Applicant: MorphoSys AG ,  Galapagos NV

Inventor： Andreas BÜLTMANN ,  Robert MÜHLBACHER ,  Teresa GARCIA ,  Reginald Christophe Xavier BRYS ,  Luc NELLES ,  Katja CONRATH

IPC: C07K16/24

Abstract: The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder.

公开(公告)号：US20230357398A1

公开(公告)日：2023-11-09

申请号：US18246052

申请日：2021-09-22

Applicant: MORPHOSYS AG

Inventor： Andreas BÜLTMANN ,  Steffen RUNZ ,  Tschimegma BATAA ,  Markus MOOSMEIER ,  Nicole HAUBST ,  Jürgen KLATTIG ,  Yvonne STARK

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2809 ,  A61P35/00 ,  C07K2317/565 ,  C07K2317/33 ,  C07K2317/622 ,  C07K2317/55 ,  C07K2317/31

Abstract: The present disclosure provides novel fully human antibodies and antibody fragments specific for human CD3 epsilon.